Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Управление гипергликемией при сахарном диабете 2 типа, 2022. Консенсусный отчет Американской диабетической ассоциации (ADA) и Европейской ассоциации по изучению диабета (EASD)
John B. Buse, Melanie J. Davies, Sylvia E. Rosas, Stefano Del Prato, Peter Rossing, Απόστολος Τσάπας, Chantal Mathieu, Nisa M. Maruthur, Geltrude Mingrone, Billy S. Collins, Robert A. Gabbay, Vanita R. Aroda, Tsvetalina Tankova, Jennifer Green
2022-09-23

ADA–EASD consensus report 2022Management of hyperglycemia in type 2 diabetescardiorenal protection and outcomes trialsglucagon-like peptide 1 receptor agonists (GLP-1 RAs)sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
1
A multidisciplinary panel updated consensus recommendations for managing hyperglycemia in adults with type 2 diabetes, based on literature since 2018.
2
Cardiovascular and kidney outcomes trials of SGLT2 inhibitors and GLP-1 receptor agonists inform broader recommendations for cardiorenal protection in high-risk people with diabetes.
3
Greater emphasis on weight management is recommended as part of a holistic approach to diabetes care.
4
New recommendations place additional focus on social determinants of health, health care system factors, and physical activity behaviors including sleep.
5
The consensus report includes a summary list of recommendations plus practical implementation tips for clinicians and care teams.

Management of hyperglycemia in adults with type 2 diabetes

Consensus recommendations and practical implementation guidance on treatment strategies (including weight management, SGLT2 inhibitors, GLP-1 receptor agonists), consideration of social determinants, healthcare system factors, and physical activity/sleep to achieve cardiorenal protection and overall glycemic control

Publication Details
Publication Date
2022-09-23
Journal
Publisher
ISSN
Cited by
2073
Access Type
Author Information
Authors
John B. Buse
Melanie J. Davies
Sylvia E. Rosas
Stefano Del Prato
Peter Rossing
Απόστολος Τσάπας
Chantal Mathieu
Nisa M. Maruthur
Geltrude Mingrone
Billy S. Collins
Robert A. Gabbay
Vanita R. Aroda
Tsvetalina Tankova
Jennifer Green
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%